Core Insights - Voyager Therapeutics announced positive topline data from the single ascending dose (SAD) trial of VY7523, an investigational anti-tau antibody for Alzheimer's disease, demonstrating safety, tolerability, and dose-proportional pharmacokinetics [1][2][4] - The company has initiated a multiple ascending dose (MAD) trial of VY7523 in early Alzheimer's patients, with initial tau PET imaging data expected in the second half of 2026 [1][3][4] Company Overview - Voyager Therapeutics is focused on advancing neurogenetic medicines, particularly targeting neurological diseases such as Alzheimer's, ALS, and Parkinson's [6][7] - The company utilizes its TRACER™ AAV capsid discovery platform to develop genetic medicines with high brain penetration [6][7] Alzheimer's Disease Context - Alzheimer's disease affects an estimated 7 million people in the U.S. and up to 416 million globally, leading to significant memory loss and cognitive decline [5] - The total cost of caring for individuals with Alzheimer's and other dementias in the U.S. was estimated at $345 billion in 2023 [5]

Core Insights - Voyager Therapeutics announced positive topline data from the single ascending dose (SAD) trial of VY7523, an investigational anti-tau antibody for Alzheimer's disease, demonstrating safety, tolerability, and dose-proportional pharmacokinetics [1][4] - The company has initiated a multiple ascending dose (MAD) trial of VY7523 in early Alzheimer's patients, with initial tau PET imaging data expected in the second half of 2026 [1][3] Company Overview - Voyager Therapeutics is focused on advancing neurogenetic medicines, particularly for neurological diseases such as Alzheimer's, ALS, and Parkinson's [6] - The company utilizes its TRACER™ AAV capsid discovery platform to develop novel therapies aimed at modifying the course of neurological diseases [6][7] Alzheimer's Disease Context - Alzheimer's disease affects an estimated 7 million people in the U.S. and up to 416 million globally, leading to significant memory loss and cognitive decline [5] - The total cost of caring for individuals with Alzheimer's and other dementias in the U.S. was estimated at $345 billion in 2023 [5] Clinical Trial Details - The SAD trial was randomized, double-blind, and placebo-controlled, involving 48 healthy volunteers, with no serious adverse events reported [2][3] - The MAD trial will evaluate VY7523 in 52 patients with early Alzheimer's, focusing on safety, tolerability, and the ability to prevent the spread of pathological tau [3][4] Drug Mechanism and Efficacy - VY7523 is a humanized IgG4 monoclonal antibody designed to inhibit the spread of pathological tau, which correlates with disease progression in Alzheimer's [4] - Preclinical studies indicated that VY7523 could reduce tau spread by approximately 70% [2][4] Future Expectations - Voyager anticipates presenting additional data from the SAD study at an upcoming scientific conference, which may further validate the potential of VY7523 [2][6] - Third-party data expected later this year and early next year could enhance interest in tau-targeting therapies [2]

Core Viewpoint - The Schall Law Firm is investigating Voyager Therapeutics, Inc. for potential violations of securities laws related to misleading statements and undisclosed information affecting investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Voyager issued false or misleading statements and failed to disclose critical information to investors [2]. - On February 11, 2025, Voyager announced it would assess alternate payloads for its gene therapy program targeting SOD1 amyotrophic lateral sclerosis (ALS) [2]. - The company indicated that emerging preclinical data showed the siRNA payload component of VY9323 did not meet its standards due to an off-target effect, leading to a narrowed therapeutic window [2]. - Following this announcement, Voyager's shares dropped by 20% on the same day [2]. Group 2: Shareholder Rights - The Schall Law Firm encourages shareholders who suffered losses to participate in the investigation and offers free consultations regarding their rights [3]. - The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [3].

Core Viewpoint - Kirby McInerney LLP is investigating potential claims against Voyager Therapeutics for possible violations of federal securities laws and unlawful business practices [1][3]. Company Developments - On February 11, 2025, Voyager announced it would assess alternate payloads for its gene therapy program targeting SOD1 amyotrophic lateral sclerosis (ALS), citing emerging preclinical data indicating that the siRNA payload component of VY9323 does not meet their standards due to off-target effects [3]. - Voyager stated it no longer anticipates filing an investigational new drug (IND) application for VY9323 in mid-2025 [3]. - Following this announcement, Voyager's share price fell by $1.11, or approximately 20%, from $5.32 on February 10, 2025, to $4.41 on February 11, 2025 [3].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Voyager Therapeutics and its officers or directors [1] Group 1: Company Developments - On February 11, 2025, Voyager announced it would assess alternate payloads for its gene therapy program targeting SOD1 amyotrophic lateral sclerosis (ALS), citing emerging preclinical data indicating that the siRNA payload component of VY9323 does not meet their standards due to off-target effects [2] - Following this announcement, Voyager's stock price dropped by $1.11 per share, or 20.86%, closing at $4.21 per share on the same day [2] Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [3]

- Company to assess alternate payloads; no changes planned to novel capsid component - - Resulting shift of timeline and costs extends cash runway into mid-2027 – - All other programs remain on track; IND filings expected in 2025 for GBA1 and FA programs - LEXINGTON, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it has decided to assess alternate payloads related to its gene thera ...

LEXINGTON, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will participate in a fireside chat at the Oppenheimer 25th Annual Healthcare Life Sciences Conference at 2:40 p.m. ET on February 11, 2025. A webcast of the presentation will be available and may be accessed from the Investors section of Voyager’s website at ir.voyagertherapeutics.com. A replay of the webcast will be archive ...

About six months ago, I wrote an article on Voyager Therapeutics, Inc. (NASDAQ: VYGR ) highlighting the pipeline advances and stable financial position, supporting a “Strong Buy” rating. Given that VYGR’s shares have fallen by 35% sinceOriginally a Biologist, M.Sc in Biomedicine, PhD in Bioengineerings, and +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs including orthopaedics and rare diseases. As an investor, I have been utilising m ...

Investors might want to bet on Voyager Therapeutics (VYGR) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of ...

Shares of Voyager Therapeutics (VYGR) have gained 4.2% over the past four weeks to close the last trading session at $6.93, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $17.50 indicates a potential upside of 152.5%.The average comprises 10 short-term price targets ranging from a low of $11 to a high of $30, with a standard deviation of $5.36. While the lowest estimate indicat ...